Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis

Authors:

Abstract
Context 2017 WHO Classification of Pituitary Tumors grades silent corticotroph adenomas (SCAs) as “high-risk adenomas” due to their aggressive clinical behavior (high probability of recurrence). However, studies comparing recurrence rates of SCAs with other non-functioning pituitary adenoma (NFPAs) subtypes have provided conflicting results. Objective Estimate recurrence rates of SCAs after primary treatment (surgery±radiotherapy) and recurrence rate ratios (RRR) between SCAs and other NFPA subtypes. Methods Systematic review of published literature reporting on outcomes of SCAs up to October 31, 2017 was conducted. Recurrence rates, RRRs, 95% confidence intervals (CIs) were estimated from each study and pooled using random effects meta-analysis model. Results For determination of SCAs recurrence rates, 14 studies (low risk of bias, 297 patients) were selected; recurrence rate was 5.96 (95% CI, 4.3-7.84) per 100 person-years. Based on studies with mean follow-up p=0.130) between the groups. Focus on tumors treated solely by surgery also revealed no significant RRR (1.17; 95% CI, 0.79-1.75, p=0.429). Conclusions Based on studies with mean follow-up ≥5 years, 31% of SCAs have recurrence. No evidence supporting higher recurrence risk of SCAs compared with other NFPA subtypes was found.